Bioject Announces Roche and Trimeris Update on the Use of Fuzeon(R) with Biojector(R) 2000

Bioject Announces Roche and Trimeris Update on the Use of Fuzeon(R) with Biojector(R) 2000

Business Wire - October 3, 2007

PORTLAND, Ore. -- Bioject Medical Technologies Inc. (Nasdaq:BJCT), a leading developer of needle-free drug delivery systems today announced that it has been notified by Roche and Trimeris that they will not be proceeding with their FDA submission for Fuzeon(R) to be administered with the Biojector(R) 2000 ("B2000").

"We would have preferred to see the process completed and to have been able to provide the B2000 to all HIV patients," said Ralph Makar, President and Chief Executive Officer of Bioject. "Our device offers benefits over the use of needle and syringe for the delivery of injectables, as millions of injections have been administered by the B2000 since its release by the FDA in 1993. We continue to pursue other opportunities with current and new partners for its use in benefiting patients."

"We are pleased that patients who are currently delivering Fuzeon with the B2000 through existing programs and clinical trials may continue to do so," said Dr. Richard Stout, Executive Vice President and Chief Medical Officer. "We realize the need for alternatives to the needle and syringe to reduce injection site reaction as suggested in the clinical trials and we look forward to learning more from the on-going clinical trials."

Bioject Medical Technologies Inc., based in Portland, Oregon, is an innovative developer and manufacturer of needle-free drug delivery systems. Needle-free injection works by forcing medication at high speed through a tiny orifice held against the skin. This creates a fine stream of high-pressure fluid penetrating the skin and depositing medication in the tissue beneath. The Company is focused on developing mutually beneficial agreements with leading pharmaceutical, biotechnology, and veterinary companies.

For more information on Bioject, visit www.bioject.com.

---

Contacts:

Bioject Medical Technologies Inc.

President and Chief Executive Officer

Ralph Makar, 503-692-8001 ext. 4137

Executive Vice President and Chief Medical Officer

Dr. Richard Stout, 503-692-8001 ext. 4130

071003
BW071006

Copyright © 2007 - Business Wire. All rights reserved. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through the Business Wire, Permissions Desk, Business Wire, 1185 Avenue of the Americas, 3rd Floor, New York, NY 10036; Tel: (212) 575-8822; FAX: (212) 575-1854. http://www.businesswire.com.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, the National Library of Medicine, Pacific Life Foundation and donations from users like you.

Always watch for outdated information. This article first appeared in 2007. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2007. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .